Drug Trial Radar · NCT07849231
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Jun 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- Damora TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.
Conditions
- Myeloproliferative Neoplasms (MPNs)
Interventions
DMR-001Drug
DMR-001 will be administered at protocol defined dose at a frequency of every 4 weeks.
RuxolitinibDrug
Ruxolitinib will be administered according to Prescribing Information/SmPC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of DMR-001 & determine the MTD, RDE(s), and/or recommended Phase 2 dose(s) in participants with CALR-mutant MPNs, when administered as monotherapy or in combination with ruxolitinibTime frame: Up to 672 days
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
Site US07
Birmingham, Alabama · Not yet recruiting
Site US26
Gilbert, Arizona · Not yet recruiting
Site US11
Duarte, California · Not yet recruiting
Site US25
Irvine, California · Not yet recruiting
Site US04
Tampa, Florida · Not yet recruiting
Site US15
Atlanta, Georgia · Not yet recruiting
Site US21
Kansas City, Kansas · Not yet recruiting
Site US18
Baltimore, Maryland · Not yet recruiting
Site US03
Boston, Massachusetts · Not yet recruiting
Site US12
Boston, Massachusetts · Not yet recruiting
Site US06
Ann Arbor, Michigan · Not yet recruiting
Site US08
St Louis, Missouri · Not yet recruiting
Site US17
Babylon, New York · Not yet recruiting
Site US01
New York, New York · Not yet recruiting
Site US02
New York, New York · Not yet recruiting
Site US14
Charlotte, North Carolina · Not yet recruiting
Site US24
Durham, North Carolina · Not yet recruiting
Site US13
Winston-Salem, North Carolina · Not yet recruiting
Site US05
Columbus, Ohio · Not yet recruiting
Site US20
Eugene, Oregon · Not yet recruiting
Site US19
Nashville, Tennessee · Not yet recruiting
Site US10
Houston, Texas · Not yet recruiting
Site US16
Salt Lake City, Utah · Not yet recruiting
Site US23
Richmond, Virginia · Not yet recruiting
Site US22
Seattle, Washington · Not yet recruiting
Site AU08
Liverpool, New South Wales, Australia · Not yet recruiting
Site AU07
Newcastle, New South Wales, Australia · Not yet recruiting
Site AU06
Sydney, New South Wales, Australia · Not yet recruiting
Site AU09
Sydney, New South Wales, Australia · Recruiting
Site AU11
Brisbane, Queensland, Australia · Not yet recruiting
Site AU10
Sunshine Coast, Queensland, Australia · Not yet recruiting
Site AU01
Adelaide, South Australia, Australia · Not yet recruiting
Site AU02
Melbourne, Victoria, Australia · Recruiting
Site AU03
Melbourne, Victoria, Australia · Recruiting
Site AU04
Melbourne, Victoria, Australia · Not yet recruiting
Site AU05
Perth, Western Australia, Australia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.